Moreover, LIRA inhibited oxidative stress in diet-induced non-alcoholic fatty liver disease (NAFLD) via increasing SOD activity and reducing malondialdehyde (MDA) levels [3]. Here, SOD1 is linked to metabolic dysfunction-associated steatotic liver disease.